UK Registered Veterinary Retailer

Milbemax Worming Tablets for Dogs & Cats

Milbemax Worming Tablets for Dogs & Cats

  • Cats » Priced per Tablet £4.49
  • Medium/Large Dogs Chewable/Tasty » Priced per Tablet £4.19
  • Medium/Large Dogs » Priced per Tablet £4.90
  • Small Cats and Kittens » Priced per Tablet £2.29
  • Small Dogs/Puppies Chewable/Tasty » Priced per Tablet £1.79
  • Small Dogs/Puppies » Priced per Tablet £2.09

Selection of 6 products from

£1.79 to £4.90

Description

Milbemax is a safe and effective multi-wormer for dogs and cats, available in three different forms. There are small, easy to swallow tablets available for cats and for dogs. These are designed to be placed directly into the animals mouth. There are also chewable tablets available for dogs, which can be offered as treats or in a meal. Milbemax can be used for the treatment of mixed infections by tapeworms, roundworms, lungworms and eye worm, as well as the prevention of heartworm and angiostrongylosis. There are a number of different dosing schedules used, depending on the type of worm being targeted and the degree of risk of infection. Please check the following table to ensure you order the correct tablets if ordering for your pet:

Pet size Tablet type
Puppies & Dogs weighing 1-5kg Small Dogs/Puppies
Dogs weighing over 5kg Medium/Large Dogs
Kittens & Cats weighing up to 2kg Small Cats and Kittens
Cats weighing between 2 - 12kg Cats

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

Cats » Priced per Tablet

Milbemax Tablets for Cats

Qualitative and quantitative composition

One tablet contains:

Active substances:

Milbemycin oxime 16 mg

Praziquantel 40 mg

Excipients:

Iron oxide (E172) 0.288 mg

Excipients QS one divisible tablet of 132.5 mg

For a full list of excipients, see Pharmaceutical Particulars.

Pharmaceutical form

Film-coated tablet.

Oblong shaped, reddish to reddish brown, artificial beef flavoured tablet with a score on both sides. One side bears the imprint “KK”, the other side “NA”.

Clinical particulars

Target species

Cats.

Indications for use, specifying the target species

In cats: treatment of mixed infections by immature and adult cestodes and nematodes of the following species :

- Cestodes:

Dipylidium caninum

Taenia spp.

Echinococcus multilocularis

- Nematodes:

Ancylostoma tubaeforme

Toxocara cati

Prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.

Contraindications

Do not use in cats weighing less than 2 kg.

Special warnings

None

Special precautions for use

Special precautions for use in animals

As per good veterinary practice, animals should be weighed to ensure accurate dosing.

Echinococcosis represents a hazard for humans. In case of Echinococcosis, specific

guidelines on the treatment and follow up and on the safeguard of persons have to be followed. Experts or institutes of parasitology should be consulted.

No studies have been performed with severely debilitated cats or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the doctor.

Adverse reactions (frequency and seriousness)

In very rare occasions, especially in young cats, systemic signs (such as lethargy), neurological signs (such as ataxia and muscle tremors) and/or gastrointestinal signs (such as emesis and diarrhoea) have been observed after administration of the veterinary medicinal product.

Use during pregnancy, lactation or lay

MILBEMAX can be used in breeding cats including pregnant and lactating queens.

Interaction with other medicinal products and other forms of interaction

The concurrent use of MILBEMAX with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with MILBEMAX at the recommended dose.

Although not recommended, the concomitant use of MILBEMAX with a spot on containing moxidectin and imidacloprid at recommended dose rates following a single application was well tolerated in one laboratory study in 10 kittens.

The safety and efficacy of the concurrent use have not been investigated in field studies. In the absence of further studies, caution should be taken in the case of concurrent use of the product with any other macrocyclic lactone. Also, no such studies have been performed with reproducing animals.

Amounts to be administered and administration route

Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given orally as a single dose. The product should be administered with or after some food. Doing so ensures optimum protection against heartworm disease

Depending on the bodyweight of the cat, the practical dosing is as follows:

WeightTablets2 - 4 kg½ tablet>4 - 8 kg1 tablet>8 - 12 kg1½ tablets

Weight

Tablets

2 - 4 kg

½ tablet

>4 - 8 kg

1 tablet

>8 - 12 kg

1½ tablets

MILBEMAX can be inserted into a programme for prevention of heartworm disease if at the same time treatment against tapeworms is indicated. MILBEMAX has a duration of heartworm prevention of one month. For regular prevention of heartworm disease the use of a monosubstance is preferred.

Overdose (symptoms, emergency procedures, antidotes), if necessary

In case of overdose, in addition to signs observed at the recommended dose (see "Adverse reactions"), drooling was observed. This sign will usually disappear spontaneously within a day.

Withdrawal period(s)

Not applicable.

Pharmacological particulars

Pharmacotherapeutic group: Antiparasitic products, insecticides and repellants - endectocides

ATCvet Code: QP54AB51 (milbemycin oxime, combinations)

Pharmacodynamic properties

Milbemycin oxime belongs to the group of macrocyclic lactones, isolated from the fermentation of Streptomyces hygroscopicus var. aureolacrimosus. It is active against mites, against larval and adult stages of nematodes as well as against larvae of Dirofilaria immitis.

The activity of milbemycin is related to its action on invertebrate neurotransmission: Milbemycin oxime, like avermectins and other milbemycins, increases nematode and insect membrane permeability to chloride ions via glutamate-gated chloride ion channels (related to vertebrate GABAA and glycine receptors). This leads to hyperpolarisation of the neuromuscular membrane and flaccid paralysis and death of the parasite.

Praziquantel is an acylated pyrazino-isoquinoline derivative. Praziquantel is active against cestodes and trematodes. It modifies the permeability for calcium (influx of Ca2+) in the membranes of the parasite inducing an imbalance in the membrane structures, leading to membrane depolarisation and almost instantaneous contraction of the musculature (tetany), rapid vacuolization of the syncytial tegument and subsequent tegumental disintegration (blebbing), resulting in easier expulsion from the gastrointestinal tract or death of the parasite.

Pharmacokinetic particulars

In the cat, praziquantel reaches peak plasma concentrations within an hour after oral administration.

The half life of elimination is around 3 hours.

In the dog, there is rapid hepatic biotransformation, prinicipally to monohydroxylated derivatives.

The principal route of elimination in the dog is renal.

After oral administration in the cat, milbemycin oxime reaches peak plasma concentrations within 2 hours. The half life of elimination is around 13 hours (± 9 hours).

In the rat, metabolism appears to be complete although slow, since unchanged milbemycin oxime has not been found in urine or feces. Main metabolites in the rat are monohydroxylated derivatives, attributable to hepatic biotransformation. In addition to relatively high liver concentrations, there is some concentration in fat, reflecting its lipophilicity.

Pharmaceutical particulars

List of excipients

Core:

Cellulose, microcristalline

Croscarmellose sodium

Povidone

Lactose monohydrate

Silica, colloidal anhydrous

Magnesium stearate

Coat:

Hypromellose

Macrogol

Talc

Iron oxide red

Artificial beef flavour

Incompatibilities

Not applicable.

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years

Shelf-life after first opening of the immediate packaging: 6 months

Special precautions for storage

Do not store above 25°C.

Keep blister in the outer carton to protect from light.

Nature and composition of immediate packaging

PVC/PE/PVdC/aluminium blister

Available pack sizes:

Box with 2 tablets in blister

Box with 4 tablets in blister

Box with 10 tablets in blister

Box with 20 tablets in blister

Box with 50 tablets in blister

Box with 100 tablets in blister

Not all pack sizes may be marketed.

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste material should be disposed of in accordance with national requirements.

The product should not enter water courses as this may be dangerous for fish and other aquatic organisms.

Marketing Authorisation Holder (if different from distributor)

NA

Marketing Authorisation Number

Vm 00879/4042

Date of the first authorisation or date of renewal

17 April 2003

Date of revision of the text

March 2016

Any other information

Legal category

Medium/Large Dogs » Priced per Tablet

Milbemax Tablets for dogs

Qualitative and quantitative composition

Active substances:

Milbemycin oxime 12.5 mg

Praziquantel 125.0 mg

Excipients:

QSP one tablet of 625 mg

For a full list of excipients, see Pharmaceutical Particulars.

Pharmaceutical form

Tablet

Round shaped, white. One side bears the imprint “CCA”, the other side “NA”.

Clinical particulars

Target species

Dogs

Indications for use, specifying the target species

In dogs: treatment of mixed infections by adult cestodes and nematodes of the following species:

- Cestodes:

Dipylidium caninum

Taenia spp.

Echinococcus spp.

Mesocestoides spp.

- Nematodes:

Ancylostoma caninum

Toxocara canis

Toxascaris leonina

Trichuris vulpis

Crenosoma vulpis (Reduction of the level of infection)

Angiostrongylus vasorum (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under "Amounts to be administered and administration route”)

Thelazia callipaeda (see specific treatment schedule under “Amounts to be administered and administration route”)

The product can also be used in the prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.

Contraindications

Do not use in dogs weighing less than 5 kg

Do not use in case of hypersensitivity to the active substances or to any of the excipients

See also point "Special precautions for use"

Special warnings for each target species

Studies with milbemycin oxime indicate that the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed.

The tolerance of MILBEMAX in young puppies from these breeds has not been investigated.

Clinical signs in Collies are similar to those seen in the general dog population when overdosed (see overdose section).

Special precautions for use, including special precautions to be taken by the person administering the medicinal product to animals

Special precautions for use in animals

As per good veterinary practice, animals should be weighed to ensure accurate dosing

Treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product. The use in dogs suffering from microfilaremia is thus not recommended.

In heartworm risk-areas, or in the case it is known that a dog has been travelling to and from heartworm risk regions, before using MILBEMAX, a veterinary consultation is advised to exclude the presence of any concurrent infestation of Dirofilaria immitis. In the case of a positive diagnosis, adulticidal therapy is indicated before administering Milbemax.

Echinococcosis represents a hazard for humans. In case of Echinococcosis, specific guidelines on the treatment and follow up and on the safeguard of persons have to be followed. Experts or institutes of parasitology should be consulted.

No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

In dogs less than 4 weeks old, tape worm infection is unusual. Treatment of animals less than 4 weeks old with a combination product may therefore not be necessary.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the doctor.

Adverse reactions (frequency and seriousness)

In very rare occasions, systemic signs (such as lethargy), neurological signs (such as muscle tremors and ataxia) and/or gastrointestinal signs (such as emesis, diarrhea, anorexia and drooling have been observed in dogs after administration of the veterinary medicinal product.

Use during pregnancy, lactation or lay

The product may be used in breeding dogs including pregnant and lactating bitches.

Interaction with other medicinal products and other forms of interaction

The concurrent use of MILBEMAX with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with MILBEMAX at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of MILBEMAX and other macrocyclic lactones. Also, no such studies have been performed with reproducing animals.

Amounts to be administered and administration route

Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.

The product should be administered with or after some food.

Depending on the bodyweight of the dog, the practical dosing is as follows:WeightTablets5 – 25 kg1 tablet>25 – 50 kg2 tablets >50 – 75 kg3 tablets

Weight

Tablets

5 – 25 kg

1 tablet

>25 – 50 kg

2 tablets

>50 – 75 kg

3 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, MILBEMAX can replace the monovalent product for the prevention of heartworm disease.

For treatment of Angiostrongylus vasorum infections , milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with MILBEMAX and continue with the monovalent product containing milbemycin oxime alone, for the remaining three weekly treatments.

In endemic areas administration of the product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against cestodes is indicated.

For the treatment of Thelazia callipaeda, milbemcyin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, MILBEMAX can replace the monovalent product containing milbemycin oxime alone.

For guidance on dosing intervals reference should be made to ESCCAP Guidelines which currently advise that, administration of the product every four weeks is effective against D. immitis third stage larvae (L3) and L4 which have developed within the previous 30 days and thus prevents disease caused by the adult worms. Administration of the product should begin within one month of first exposure with the last dose given within one month after the end of exposure. Before starting any prophylactic treatment, adult D. immitis (or D. repens) infections must be ruled out by testing for circulating antigen or microfilariae. Heartworm-infected animals should first be treated for adult worms; prophylactic treatment can begin around 4 weeks later.

Overdose (symptoms, emergency procedures, antidotes), if necessary

No other signs than those observed at the recommended dose have been observed (see adverse reactions)

Withdrawal period(s)

Not applicable

Pharmacological particulars

Pharmacotherapeutic group: Endectocides

ATCvet Code: QP54A B51 (Milbemycin combinations)

Pharmacodynamic properties

Milbemycin oxime belongs to the group of macrocyclic lactones, isolated from the fermentation of Streptomyces hygroscopicus var. aureolacrimosus. It is active against mites, against larval and adult stages of nematodes as well as against larvae of Dirofilaria immitis.

The activity of milbemycin is related to its action on invertebrate neurotransmission: Milbemycin oxime, like avermectins and other milbemycins, increases nematode and insect membrane permeability to chloride ions via glutamate-gated chloride ion channels (related to vertebrate GABAA and glycine receptors). This leads to hyperpolarisation of the neuromuscular membrane and flaccid paralysis and death of the parasite.

Praziquantel is an acylated pyrazino-isoquinoline derivative. Praziquantel is active against cestodes and trematodes. It modifies the permeability for calcium (influx of Ca2+) in the membranes of the parasite inducing an imbalance in the membrane structures, leading to membrane depolarisation and almost instantaneous contraction of the musculature (tetany), rapid vacuolization of the syncytial tegument and subsequent tegumental disintegration (blebbing), resulting in easier expulsion from the gastrointestinal tract or death of the parasite

Pharmacokinetic particulars

After oral administration of praziquantel in the dog, peak serum levels of parent are rapidly attained (Tmax approximately 0.5-4 hours) and decline quickly (t1/2 approximately 1.5 hours); there is a substantial hepatic first-pass effect, with very rapid and almost complete hepatic biotransformation, principally to monohydroxylated (also some di- and tri-hydroxylated) derivatives, which are mostly glucuronide and/or sulfate conjugated before excretion. Plasma binding is about 80%. Excretion is fast and complete (about 90% in 2 days); the principal route of elimination is renal.

After oral administration of milbemycin oxime in dogs, peak plasma levels occur at about 2-4 hours, and decline with a half-life of the unmetabolised milbemycin oxime of 1-4 days. Bioavailability is about 80%.

In the rat, metabolism appears to be complete although slow, since unchanged milbemycin oxime has not been found in urine or feces. Main metabolites in the rat are monohydroxylated derivatives, attributable to hepatic biotransformation. In addition to relatively high liver concentrations, there is some concentration in fat, reflecting its lipophilicity

Pharmaceutical particulars

List of excipients

Cellulose, microcristalline

Croscarmellose sodium

Povidone

Lactose monohydrate

Silica, colloidal anhydrous

Magnesium stearate

Incompatibilities

Not applicable

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale:

2 years

Special precautions for storage

Do not store above 30°C

Keep blister in the outer carton to protect from light

Nature and composition of immediate packaging

PVC/PE/PVdC/aluminium blister

Available pack sizes:

Box with 2 tablets in blister

Box with 4 tablets in blister

Box with 10 tablets in blister

Box with 20 tablets in blister

Box with 50 tablets in blister

Box with 100 tablets in blister

Not all pack sizes may be marketed

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste material should be disposed of in accordance with national requirements. The product should not come into contact with (IE's proposal) water courses as this may be dangerous for fish and other aquatic organisms

Marketing Authorisation Holder (if different from distributor)

NA

Marketing Authorisation Number

Vm 00879/4040

Date of the first authorisation or date of renewal

17 April 2003

Date of revision of the text

March 2016

Any other information

Legal category

Small Dogs/Puppies » Priced per Tablet

Milbemax Tablets for dogs

Qualitative and quantitative composition

Active substances:

Milbemycin oxime 12.5 mg

Praziquantel 125.0 mg

Excipients:

QSP one tablet of 625 mg

For a full list of excipients, see Pharmaceutical Particulars.

Pharmaceutical form

Tablet

Round shaped, white. One side bears the imprint “CCA”, the other side “NA”.

Clinical particulars

Target species

Dogs

Indications for use, specifying the target species

In dogs: treatment of mixed infections by adult cestodes and nematodes of the following species:

- Cestodes:

Dipylidium caninum

Taenia spp.

Echinococcus spp.

Mesocestoides spp.

- Nematodes:

Ancylostoma caninum

Toxocara canis

Toxascaris leonina

Trichuris vulpis

Crenosoma vulpis (Reduction of the level of infection)

Angiostrongylus vasorum (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under "Amounts to be administered and administration route”)

Thelazia callipaeda (see specific treatment schedule under “Amounts to be administered and administration route”)

The product can also be used in the prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.

Contraindications

Do not use in dogs weighing less than 5 kg

Do not use in case of hypersensitivity to the active substances or to any of the excipients

See also point "Special precautions for use"

Special warnings for each target species

Studies with milbemycin oxime indicate that the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed.

The tolerance of MILBEMAX in young puppies from these breeds has not been investigated.

Clinical signs in Collies are similar to those seen in the general dog population when overdosed (see overdose section).

Special precautions for use, including special precautions to be taken by the person administering the medicinal product to animals

Special precautions for use in animals

As per good veterinary practice, animals should be weighed to ensure accurate dosing

Treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product. The use in dogs suffering from microfilaremia is thus not recommended.

In heartworm risk-areas, or in the case it is known that a dog has been travelling to and from heartworm risk regions, before using MILBEMAX, a veterinary consultation is advised to exclude the presence of any concurrent infestation of Dirofilaria immitis. In the case of a positive diagnosis, adulticidal therapy is indicated before administering Milbemax.

Echinococcosis represents a hazard for humans. In case of Echinococcosis, specific guidelines on the treatment and follow up and on the safeguard of persons have to be followed. Experts or institutes of parasitology should be consulted.

No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

In dogs less than 4 weeks old, tape worm infection is unusual. Treatment of animals less than 4 weeks old with a combination product may therefore not be necessary.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the doctor.

Adverse reactions (frequency and seriousness)

In very rare occasions, systemic signs (such as lethargy), neurological signs (such as muscle tremors and ataxia) and/or gastrointestinal signs (such as emesis, diarrhea, anorexia and drooling have been observed in dogs after administration of the veterinary medicinal product.

Use during pregnancy, lactation or lay

The product may be used in breeding dogs including pregnant and lactating bitches.

Interaction with other medicinal products and other forms of interaction

The concurrent use of MILBEMAX with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with MILBEMAX at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of MILBEMAX and other macrocyclic lactones. Also, no such studies have been performed with reproducing animals.

Amounts to be administered and administration route

Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.

The product should be administered with or after some food.

Depending on the bodyweight of the dog, the practical dosing is as follows:WeightTablets5 – 25 kg1 tablet>25 – 50 kg2 tablets >50 – 75 kg3 tablets

Weight

Tablets

5 – 25 kg

1 tablet

>25 – 50 kg

2 tablets

>50 – 75 kg

3 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, MILBEMAX can replace the monovalent product for the prevention of heartworm disease.

For treatment of Angiostrongylus vasorum infections , milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with MILBEMAX and continue with the monovalent product containing milbemycin oxime alone, for the remaining three weekly treatments.

In endemic areas administration of the product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against cestodes is indicated.

For the treatment of Thelazia callipaeda, milbemcyin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, MILBEMAX can replace the monovalent product containing milbemycin oxime alone.

For guidance on dosing intervals reference should be made to ESCCAP Guidelines which currently advise that, administration of the product every four weeks is effective against D. immitis third stage larvae (L3) and L4 which have developed within the previous 30 days and thus prevents disease caused by the adult worms. Administration of the product should begin within one month of first exposure with the last dose given within one month after the end of exposure. Before starting any prophylactic treatment, adult D. immitis (or D. repens) infections must be ruled out by testing for circulating antigen or microfilariae. Heartworm-infected animals should first be treated for adult worms; prophylactic treatment can begin around 4 weeks later.

Overdose (symptoms, emergency procedures, antidotes), if necessary

No other signs than those observed at the recommended dose have been observed (see adverse reactions)

Withdrawal period(s)

Not applicable

Pharmacological particulars

Pharmacotherapeutic group: Endectocides

ATCvet Code: QP54A B51 (Milbemycin combinations)

Pharmacodynamic properties

Milbemycin oxime belongs to the group of macrocyclic lactones, isolated from the fermentation of Streptomyces hygroscopicus var. aureolacrimosus. It is active against mites, against larval and adult stages of nematodes as well as against larvae of Dirofilaria immitis.

The activity of milbemycin is related to its action on invertebrate neurotransmission: Milbemycin oxime, like avermectins and other milbemycins, increases nematode and insect membrane permeability to chloride ions via glutamate-gated chloride ion channels (related to vertebrate GABAA and glycine receptors). This leads to hyperpolarisation of the neuromuscular membrane and flaccid paralysis and death of the parasite.

Praziquantel is an acylated pyrazino-isoquinoline derivative. Praziquantel is active against cestodes and trematodes. It modifies the permeability for calcium (influx of Ca2+) in the membranes of the parasite inducing an imbalance in the membrane structures, leading to membrane depolarisation and almost instantaneous contraction of the musculature (tetany), rapid vacuolization of the syncytial tegument and subsequent tegumental disintegration (blebbing), resulting in easier expulsion from the gastrointestinal tract or death of the parasite

Pharmacokinetic particulars

After oral administration of praziquantel in the dog, peak serum levels of parent are rapidly attained (Tmax approximately 0.5-4 hours) and decline quickly (t1/2 approximately 1.5 hours); there is a substantial hepatic first-pass effect, with very rapid and almost complete hepatic biotransformation, principally to monohydroxylated (also some di- and tri-hydroxylated) derivatives, which are mostly glucuronide and/or sulfate conjugated before excretion. Plasma binding is about 80%. Excretion is fast and complete (about 90% in 2 days); the principal route of elimination is renal.

After oral administration of milbemycin oxime in dogs, peak plasma levels occur at about 2-4 hours, and decline with a half-life of the unmetabolised milbemycin oxime of 1-4 days. Bioavailability is about 80%.

In the rat, metabolism appears to be complete although slow, since unchanged milbemycin oxime has not been found in urine or feces. Main metabolites in the rat are monohydroxylated derivatives, attributable to hepatic biotransformation. In addition to relatively high liver concentrations, there is some concentration in fat, reflecting its lipophilicity

Pharmaceutical particulars

List of excipients

Cellulose, microcristalline

Croscarmellose sodium

Povidone

Lactose monohydrate

Silica, colloidal anhydrous

Magnesium stearate

Incompatibilities

Not applicable

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale:

2 years

Special precautions for storage

Do not store above 30°C

Keep blister in the outer carton to protect from light

Nature and composition of immediate packaging

PVC/PE/PVdC/aluminium blister

Available pack sizes:

Box with 2 tablets in blister

Box with 4 tablets in blister

Box with 10 tablets in blister

Box with 20 tablets in blister

Box with 50 tablets in blister

Box with 100 tablets in blister

Not all pack sizes may be marketed

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste material should be disposed of in accordance with national requirements. The product should not come into contact with (IE's proposal) water courses as this may be dangerous for fish and other aquatic organisms

Marketing Authorisation Holder (if different from distributor)

NA

Marketing Authorisation Number

Vm 00879/4040

Date of the first authorisation or date of renewal

17 April 2003

Date of revision of the text

March 2016

Any other information

Legal category

Small Dogs/Puppies Chewable/Tasty » Priced per Tablet

Milbemax Tablets for dogs

Qualitative and quantitative composition

Active substances:

Milbemycin oxime 12.5 mg

Praziquantel 125.0 mg

Excipients:

QSP one tablet of 625 mg

For a full list of excipients, see Pharmaceutical Particulars.

Pharmaceutical form

Tablet

Round shaped, white. One side bears the imprint “CCA”, the other side “NA”.

Clinical particulars

Target species

Dogs

Indications for use, specifying the target species

In dogs: treatment of mixed infections by adult cestodes and nematodes of the following species:

- Cestodes:

Dipylidium caninum

Taenia spp.

Echinococcus spp.

Mesocestoides spp.

- Nematodes:

Ancylostoma caninum

Toxocara canis

Toxascaris leonina

Trichuris vulpis

Crenosoma vulpis (Reduction of the level of infection)

Angiostrongylus vasorum (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under "Amounts to be administered and administration route”)

Thelazia callipaeda (see specific treatment schedule under “Amounts to be administered and administration route”)

The product can also be used in the prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.

Contraindications

Do not use in dogs weighing less than 5 kg

Do not use in case of hypersensitivity to the active substances or to any of the excipients

See also point "Special precautions for use"

Special warnings for each target species

Studies with milbemycin oxime indicate that the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed.

The tolerance of MILBEMAX in young puppies from these breeds has not been investigated.

Clinical signs in Collies are similar to those seen in the general dog population when overdosed (see overdose section).

Special precautions for use, including special precautions to be taken by the person administering the medicinal product to animals

Special precautions for use in animals

As per good veterinary practice, animals should be weighed to ensure accurate dosing

Treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product. The use in dogs suffering from microfilaremia is thus not recommended.

In heartworm risk-areas, or in the case it is known that a dog has been travelling to and from heartworm risk regions, before using MILBEMAX, a veterinary consultation is advised to exclude the presence of any concurrent infestation of Dirofilaria immitis. In the case of a positive diagnosis, adulticidal therapy is indicated before administering Milbemax.

Echinococcosis represents a hazard for humans. In case of Echinococcosis, specific guidelines on the treatment and follow up and on the safeguard of persons have to be followed. Experts or institutes of parasitology should be consulted.

No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

In dogs less than 4 weeks old, tape worm infection is unusual. Treatment of animals less than 4 weeks old with a combination product may therefore not be necessary.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the doctor.

Adverse reactions (frequency and seriousness)

In very rare occasions, systemic signs (such as lethargy), neurological signs (such as muscle tremors and ataxia) and/or gastrointestinal signs (such as emesis, diarrhea, anorexia and drooling have been observed in dogs after administration of the veterinary medicinal product.

Use during pregnancy, lactation or lay

The product may be used in breeding dogs including pregnant and lactating bitches.

Interaction with other medicinal products and other forms of interaction

The concurrent use of MILBEMAX with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with MILBEMAX at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of MILBEMAX and other macrocyclic lactones. Also, no such studies have been performed with reproducing animals.

Amounts to be administered and administration route

Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.

The product should be administered with or after some food.

Depending on the bodyweight of the dog, the practical dosing is as follows:WeightTablets5 – 25 kg1 tablet>25 – 50 kg2 tablets >50 – 75 kg3 tablets

Weight

Tablets

5 – 25 kg

1 tablet

>25 – 50 kg

2 tablets

>50 – 75 kg

3 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, MILBEMAX can replace the monovalent product for the prevention of heartworm disease.

For treatment of Angiostrongylus vasorum infections , milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with MILBEMAX and continue with the monovalent product containing milbemycin oxime alone, for the remaining three weekly treatments.

In endemic areas administration of the product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against cestodes is indicated.

For the treatment of Thelazia callipaeda, milbemcyin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, MILBEMAX can replace the monovalent product containing milbemycin oxime alone.

For guidance on dosing intervals reference should be made to ESCCAP Guidelines which currently advise that, administration of the product every four weeks is effective against D. immitis third stage larvae (L3) and L4 which have developed within the previous 30 days and thus prevents disease caused by the adult worms. Administration of the product should begin within one month of first exposure with the last dose given within one month after the end of exposure. Before starting any prophylactic treatment, adult D. immitis (or D. repens) infections must be ruled out by testing for circulating antigen or microfilariae. Heartworm-infected animals should first be treated for adult worms; prophylactic treatment can begin around 4 weeks later.

Overdose (symptoms, emergency procedures, antidotes), if necessary

No other signs than those observed at the recommended dose have been observed (see adverse reactions)

Withdrawal period(s)

Not applicable

Pharmacological particulars

Pharmacotherapeutic group: Endectocides

ATCvet Code: QP54A B51 (Milbemycin combinations)

Pharmacodynamic properties

Milbemycin oxime belongs to the group of macrocyclic lactones, isolated from the fermentation of Streptomyces hygroscopicus var. aureolacrimosus. It is active against mites, against larval and adult stages of nematodes as well as against larvae of Dirofilaria immitis.

The activity of milbemycin is related to its action on invertebrate neurotransmission: Milbemycin oxime, like avermectins and other milbemycins, increases nematode and insect membrane permeability to chloride ions via glutamate-gated chloride ion channels (related to vertebrate GABAA and glycine receptors). This leads to hyperpolarisation of the neuromuscular membrane and flaccid paralysis and death of the parasite.

Praziquantel is an acylated pyrazino-isoquinoline derivative. Praziquantel is active against cestodes and trematodes. It modifies the permeability for calcium (influx of Ca2+) in the membranes of the parasite inducing an imbalance in the membrane structures, leading to membrane depolarisation and almost instantaneous contraction of the musculature (tetany), rapid vacuolization of the syncytial tegument and subsequent tegumental disintegration (blebbing), resulting in easier expulsion from the gastrointestinal tract or death of the parasite

Pharmacokinetic particulars

After oral administration of praziquantel in the dog, peak serum levels of parent are rapidly attained (Tmax approximately 0.5-4 hours) and decline quickly (t1/2 approximately 1.5 hours); there is a substantial hepatic first-pass effect, with very rapid and almost complete hepatic biotransformation, principally to monohydroxylated (also some di- and tri-hydroxylated) derivatives, which are mostly glucuronide and/or sulfate conjugated before excretion. Plasma binding is about 80%. Excretion is fast and complete (about 90% in 2 days); the principal route of elimination is renal.

After oral administration of milbemycin oxime in dogs, peak plasma levels occur at about 2-4 hours, and decline with a half-life of the unmetabolised milbemycin oxime of 1-4 days. Bioavailability is about 80%.

In the rat, metabolism appears to be complete although slow, since unchanged milbemycin oxime has not been found in urine or feces. Main metabolites in the rat are monohydroxylated derivatives, attributable to hepatic biotransformation. In addition to relatively high liver concentrations, there is some concentration in fat, reflecting its lipophilicity

Pharmaceutical particulars

List of excipients

Cellulose, microcristalline

Croscarmellose sodium

Povidone

Lactose monohydrate

Silica, colloidal anhydrous

Magnesium stearate

Incompatibilities

Not applicable

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale:

2 years

Special precautions for storage

Do not store above 30°C

Keep blister in the outer carton to protect from light

Nature and composition of immediate packaging

PVC/PE/PVdC/aluminium blister

Available pack sizes:

Box with 2 tablets in blister

Box with 4 tablets in blister

Box with 10 tablets in blister

Box with 20 tablets in blister

Box with 50 tablets in blister

Box with 100 tablets in blister

Not all pack sizes may be marketed

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste material should be disposed of in accordance with national requirements. The product should not come into contact with (IE's proposal) water courses as this may be dangerous for fish and other aquatic organisms

Marketing Authorisation Holder (if different from distributor)

NA

Marketing Authorisation Number

Vm 00879/4040

Date of the first authorisation or date of renewal

17 April 2003

Date of revision of the text

March 2016

Any other information

Legal category

Medium/Large Dogs Chewable/Tasty » Priced per Tablet

Milbemax Tablets for dogs

Qualitative and quantitative composition

Active substances:

Milbemycin oxime 12.5 mg

Praziquantel 125.0 mg

Excipients:

QSP one tablet of 625 mg

For a full list of excipients, see Pharmaceutical Particulars.

Pharmaceutical form

Tablet

Round shaped, white. One side bears the imprint “CCA”, the other side “NA”.

Clinical particulars

Target species

Dogs

Indications for use, specifying the target species

In dogs: treatment of mixed infections by adult cestodes and nematodes of the following species:

- Cestodes:

Dipylidium caninum

Taenia spp.

Echinococcus spp.

Mesocestoides spp.

- Nematodes:

Ancylostoma caninum

Toxocara canis

Toxascaris leonina

Trichuris vulpis

Crenosoma vulpis (Reduction of the level of infection)

Angiostrongylus vasorum (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under "Amounts to be administered and administration route”)

Thelazia callipaeda (see specific treatment schedule under “Amounts to be administered and administration route”)

The product can also be used in the prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.

Contraindications

Do not use in dogs weighing less than 5 kg

Do not use in case of hypersensitivity to the active substances or to any of the excipients

See also point "Special precautions for use"

Special warnings for each target species

Studies with milbemycin oxime indicate that the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed.

The tolerance of MILBEMAX in young puppies from these breeds has not been investigated.

Clinical signs in Collies are similar to those seen in the general dog population when overdosed (see overdose section).

Special precautions for use, including special precautions to be taken by the person administering the medicinal product to animals

Special precautions for use in animals

As per good veterinary practice, animals should be weighed to ensure accurate dosing

Treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product. The use in dogs suffering from microfilaremia is thus not recommended.

In heartworm risk-areas, or in the case it is known that a dog has been travelling to and from heartworm risk regions, before using MILBEMAX, a veterinary consultation is advised to exclude the presence of any concurrent infestation of Dirofilaria immitis. In the case of a positive diagnosis, adulticidal therapy is indicated before administering Milbemax.

Echinococcosis represents a hazard for humans. In case of Echinococcosis, specific guidelines on the treatment and follow up and on the safeguard of persons have to be followed. Experts or institutes of parasitology should be consulted.

No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.

In dogs less than 4 weeks old, tape worm infection is unusual. Treatment of animals less than 4 weeks old with a combination product may therefore not be necessary.

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the doctor.

Adverse reactions (frequency and seriousness)

In very rare occasions, systemic signs (such as lethargy), neurological signs (such as muscle tremors and ataxia) and/or gastrointestinal signs (such as emesis, diarrhea, anorexia and drooling have been observed in dogs after administration of the veterinary medicinal product.

Use during pregnancy, lactation or lay

The product may be used in breeding dogs including pregnant and lactating bitches.

Interaction with other medicinal products and other forms of interaction

The concurrent use of MILBEMAX with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with MILBEMAX at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of MILBEMAX and other macrocyclic lactones. Also, no such studies have been performed with reproducing animals.

Amounts to be administered and administration route

Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.

The product should be administered with or after some food.

Depending on the bodyweight of the dog, the practical dosing is as follows:WeightTablets5 – 25 kg1 tablet>25 – 50 kg2 tablets >50 – 75 kg3 tablets

Weight

Tablets

5 – 25 kg

1 tablet

>25 – 50 kg

2 tablets

>50 – 75 kg

3 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, MILBEMAX can replace the monovalent product for the prevention of heartworm disease.

For treatment of Angiostrongylus vasorum infections , milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with MILBEMAX and continue with the monovalent product containing milbemycin oxime alone, for the remaining three weekly treatments.

In endemic areas administration of the product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against cestodes is indicated.

For the treatment of Thelazia callipaeda, milbemcyin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, MILBEMAX can replace the monovalent product containing milbemycin oxime alone.

For guidance on dosing intervals reference should be made to ESCCAP Guidelines which currently advise that, administration of the product every four weeks is effective against D. immitis third stage larvae (L3) and L4 which have developed within the previous 30 days and thus prevents disease caused by the adult worms. Administration of the product should begin within one month of first exposure with the last dose given within one month after the end of exposure. Before starting any prophylactic treatment, adult D. immitis (or D. repens) infections must be ruled out by testing for circulating antigen or microfilariae. Heartworm-infected animals should first be treated for adult worms; prophylactic treatment can begin around 4 weeks later.

Overdose (symptoms, emergency procedures, antidotes), if necessary

No other signs than those observed at the recommended dose have been observed (see adverse reactions)

Withdrawal period(s)

Not applicable

Pharmacological particulars

Pharmacotherapeutic group: Endectocides

ATCvet Code: QP54A B51 (Milbemycin combinations)

Pharmacodynamic properties

Milbemycin oxime belongs to the group of macrocyclic lactones, isolated from the fermentation of Streptomyces hygroscopicus var. aureolacrimosus. It is active against mites, against larval and adult stages of nematodes as well as against larvae of Dirofilaria immitis.

The activity of milbemycin is related to its action on invertebrate neurotransmission: Milbemycin oxime, like avermectins and other milbemycins, increases nematode and insect membrane permeability to chloride ions via glutamate-gated chloride ion channels (related to vertebrate GABAA and glycine receptors). This leads to hyperpolarisation of the neuromuscular membrane and flaccid paralysis and death of the parasite.

Praziquantel is an acylated pyrazino-isoquinoline derivative. Praziquantel is active against cestodes and trematodes. It modifies the permeability for calcium (influx of Ca2+) in the membranes of the parasite inducing an imbalance in the membrane structures, leading to membrane depolarisation and almost instantaneous contraction of the musculature (tetany), rapid vacuolization of the syncytial tegument and subsequent tegumental disintegration (blebbing), resulting in easier expulsion from the gastrointestinal tract or death of the parasite

Pharmacokinetic particulars

After oral administration of praziquantel in the dog, peak serum levels of parent are rapidly attained (Tmax approximately 0.5-4 hours) and decline quickly (t1/2 approximately 1.5 hours); there is a substantial hepatic first-pass effect, with very rapid and almost complete hepatic biotransformation, principally to monohydroxylated (also some di- and tri-hydroxylated) derivatives, which are mostly glucuronide and/or sulfate conjugated before excretion. Plasma binding is about 80%. Excretion is fast and complete (about 90% in 2 days); the principal route of elimination is renal.

After oral administration of milbemycin oxime in dogs, peak plasma levels occur at about 2-4 hours, and decline with a half-life of the unmetabolised milbemycin oxime of 1-4 days. Bioavailability is about 80%.

In the rat, metabolism appears to be complete although slow, since unchanged milbemycin oxime has not been found in urine or feces. Main metabolites in the rat are monohydroxylated derivatives, attributable to hepatic biotransformation. In addition to relatively high liver concentrations, there is some concentration in fat, reflecting its lipophilicity

Pharmaceutical particulars

List of excipients

Cellulose, microcristalline

Croscarmellose sodium

Povidone

Lactose monohydrate

Silica, colloidal anhydrous

Magnesium stearate

Incompatibilities

Not applicable

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale:

2 years

Special precautions for storage

Do not store above 30°C

Keep blister in the outer carton to protect from light

Nature and composition of immediate packaging

PVC/PE/PVdC/aluminium blister

Available pack sizes:

Box with 2 tablets in blister

Box with 4 tablets in blister

Box with 10 tablets in blister

Box with 20 tablets in blister

Box with 50 tablets in blister

Box with 100 tablets in blister

Not all pack sizes may be marketed

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste material should be disposed of in accordance with national requirements. The product should not come into contact with (IE's proposal) water courses as this may be dangerous for fish and other aquatic organisms

Marketing Authorisation Holder (if different from distributor)

NA

Marketing Authorisation Number

Vm 00879/4040

Date of the first authorisation or date of renewal

17 April 2003

Date of revision of the text

March 2016

Any other information

Legal category

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to air freight restrictions aerosols cannot ever be sent abroad by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (20)

Q & A

Below are some recent questions we've received regarding Milbemax Worming Tablets for Dogs & Cats, including answers from our team.

10 October 2018 at 10:35am

Lungworm

Sabrina

Does milbemax for cats and milbemax for small cats and kittens treat for lungworm?

  • Customer Service Advisor

Hello,

Thank you for getting in touch.

Milbermax treats tapeworms, roundworms, lungworms and eye worm.

Hope that helps,

VioVet.

31 July 2018 at 3:33pm

Heartworms

Kwok

  • VioVet customer since 2017
  • From: South Korea, Korea, Republic of

Hi,

Does this drug also help prevention of heartworm? If no, what example of drug it does? I cannot find on your site.

Thank you

  • Customer Service Advisor

Hello,

Thank you for your question.

Milbemax can be used for the treatment of mixed infections by tapeworms, roundworms, lungworms and eye worm, as well as the prevention of heartworm and angiostrongylosis.

This is a prescription only medication so you vet would be able to advise more.

Hope that helps,

VioVet.

30 July 2018 at 10:54pm

Milbemax worming tablets - would I need a prescription from my Vet?

Jacqueline Drea

Milbemax for a medium sized dog 10 Kg - 20 Kg. Would I need to supply you with a presciption from my vet? If this is the case it would probably be easier to get it direct from the vet.

Many thanks.

  • Meds Supervisor

Hi Jacqueline,

Milbemax falls under the legal category POM-V and any medication under this category requires a prescription by law.

I hope this helps.

13 December 2015 at 5:21pm

Milbemax 1/2 tablet

Deborah

Hi. I've a new to me 5 year old rescue cat that weighs approx. 4kg. I only want to give him 1/2 a tablet since he is between the two dosage weights, but am I able to keep the other half of the table for 3 months until his next treatment or will it "go off" during that time? if I can keep it, how am i best to store it?

  • Non-Executive Director

Many people do keep part tablets in this way. It is probably acceptable if you keep them in a cool dry place. You can even wrap the part tablet tightly in a small amount of cling film to help. However I am not aware of any official tests to show if this is definitely acceptable and so I am not able to say it will definitely not "go off". It will certainly depend on the storage conditions to some extent.

12 September 2015 at 7:22am

Milbemax

Anne Dennington

How frequently should the product be administered to dogs?

  • Non-Executive Director

The general guideline is once every 3 months. Strictly speaking this is not always correct, because in some circumstances it would be better to do it more often, perhaps even once per month, whereas some dogs virtually never need a worm dose. However a sensible guide for the average adult dog is once every 3 months.

20 August 2015 at 5:17pm

Dosage

Alan Hobson

What strength i.e. per kg is reqd for a dog that weighs 30kgs !

  • Non-Executive Director

The recommended dose of the standard Milbemax tablets (not the puppy strength) is 2 tablets.

5 August 2015 at 7:45pm

Milbemax dog worming chew

joanne

should i use every month to worm my dog ? i've been getting different information from my vets about when i should worm him from monthly - 3/4 months and can i bulk buy ?

  • Non-Executive Director

This is a prescription wormer so you can only buy what your vet will allow on a written prescription. As for frequency of worming, there is no fixed rule. Theoretically it varies between dogs and takes into account the environment they are in. In practice it is difficult to know precisely what any given dog will really need, so a judgment has to be made. Personal views will affect this. Most vets would say that the average dog should be wormed with this every 3 months. Some would say every month (and this can reasonably be argued given the properties of the active ingredients and the life cycles of the various worms involved). Others would say that once or twice a year is OK. Others would say that the average adult dog does not need worming at all, unless it is in contact with children (who can theoretically pick up a type of worm from dogs). Many dogs which are never wormed do appear to be perfectly healthy. Most vets just go for a compromise somewhere in between, which is about every 3 months.

9 May 2014 at 8:58pm

Shelf-life of Milbemax

Debi Goodchild

  • VioVet customer since 2014
  • From: Cambridgeshire, United Kingdom

What is the shelf-life of Milbemax Worming Tablets? If I buy a years supply in one go will the use-by date run out?

  • Non-Executive Director

These tablets generally have a 2 year date from manufacture I believe. They will be manufactured in batches and released gradually to wholesalers, who then release them over a period. This means that there is rarely 2 years left by the time you get them I have just checked and the stock we now hold has an expiry date in March 2015. (This is clearly written on the blister packaging of every single tablet, so there can be no confusion after supply to the customer.) When you place an order with us you can request long expiry dates, but we will be governed by what we are supplied with. We tend to get through our stocks quickly, so the next batch we get in may have a longer date.